InflaRx N.V.
Business
InflaRx N.V. is a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, specifically the C5a ligand and its receptor C5aR. It develops biologic and small-molecule product candidates, including the anti‑C5a monoclonal antibodies vilobelimab and IFX002 and the oral C5aR inhibitor INF904, to selectively inhibit C5a/C5aR‑driven inflammation. Its operations span in‑house discovery, preclinical and clinical development, regulatory activities, manufacturing oversight and U.S. commercialization efforts for GOHIBIC. The company conducts clinical trials and seeks approvals in the United States, Europe and other regions, distributes via hospital channels and third‑party distributors, and pursues regional partners for broader commercialization.
Summary from filing dated 2025-03-20
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-45.60M |
| Total assets | $55.22M |
| Total liabilities | $13.66M |
| Stockholders' equity | — |
| Operating cash flow | — |